Abivax announces trading resumption of its ordinary shares on Euronext Paris
1. Abivax resumes trading on Euronext Paris after a halt. 2. Trading halt was due to a public offering announcement. 3. Company's lead candidate, ABX464, is in Phase 3 trials. 4. The company focuses on chronic inflammatory disease therapeutics. 5. The offering includes American Depositary Shares in the U.S.